Bone Metastasis (Oncology) - Drugs In Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Drugs In Development, 2021, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 7, 2, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 8, 1 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology). - The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Cancer Anorexia-Cachexia Syndrome (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2021, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape. Cancer...
175 pages •
By The Business Research Company
• Jul 2021
Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc., GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson and Company, Molecular Devices LLC, Bruker Corporation, Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc, and CytoSMART Technologies. The...
Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030 Summary Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the checkpoint inhibitors market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation. The global checkpoint inhibitors market is expected to grow from $15.29 billion in 2020 to $18.04 billion in 2021 at a compound...
Report Scope: This report aims to provide a comprehensive study of the global market for oncology pharmaceuticals (cancer drugs).It provides a detailed description of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and current and historical market revenues. The...
Myeloproliferative Disorders (MPD) Treatment market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Myeloproliferative Disorders (MPD) Treatment Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Myeloproliferative...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
Cancer Pain (Central Nervous System) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Drugs In Development, 2021, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.Cancer pain can be defined as a...
Pheochromocytoma (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2021, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.Pheochromocytoma is a rare, usually non-cancerous...
Diagnostic Imaging Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.